9- PHARMA MULTI-C...
Follow
Find
8.0K views | +22 today
Rescooped by Lionel Reichardt / le Pharmageek from 1- E-HEALTH by PHARMAGEEK
onto 9- PHARMA MULTI-CHANNEL MARKETING by PHARMAGEEK
Scoop.it!

Infographie : usage des réseaux sociaux par les professionnels de santé

Infographie : usage des réseaux sociaux par les professionnels de santé | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it
SanteConnect a réalisé le premier observatoire sur l’usage des réseaux sociaux par les professionnels de santé. Découvrez les résultats en infographie. L’usage des réseaux sociaux se développe au s...

Via Isabelle Delignière-Léglise, Agathe Quignot, Lionel Reichardt / le Pharmageek
more...
KatiaMattioli's curator insight, December 28, 2012 1:20 PM

Un observatoire sur l'usage des réseaux sociaux par les professionnels de la santé révèle une utilisation encore inégale.

9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK
MULTI CHANNEL MARKETING IN PHARMA / MULTICANAL DANS LA PHARMA
Your new post is loading...
Rescooped by Lionel Reichardt / le Pharmageek from Pharma: Trends and Uses Of Mobile Apps and Digital Marketing
Scoop.it!

Infographic: Your Digital Marketing Roadmap

Infographic: Your Digital Marketing Roadmap | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it
Infographic: Your Digital Marketing Roadmap (#Infographic: Your Digital Marketing Roadmap http://t.co/rLtKGAg2Pt #pharmamktg #epharma)

Via eMedToday
more...
No comment yet.
Rescooped by Lionel Reichardt / le Pharmageek from Pharma Marketing
Scoop.it!

Digital pharma update: loves me, loves me not?

Digital pharma update: loves me, loves me not? | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it
In her latest article, Denise Silber, founder of Doctors 2.0 & You conference, a pharmaphorum partner, explores the world of digital pharma and how this area has advanced since she last wrote for pharmaphorum. She looks at industry trends and...

Via Ash Rishi
more...
No comment yet.
Scooped by Lionel Reichardt / le Pharmageek
Scoop.it!

Industrie pharmaceutique: vaste accord entre GSK et Novartis

Industrie pharmaceutique: vaste accord entre GSK et Novartis | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it
Le groupe suisse Novartis se recentre sur certaines activités.
more...
No comment yet.
Rescooped by Lionel Reichardt / le Pharmageek from Pharma Hub
Scoop.it!

Genzyme lance un site web sur la maladie de Gaucher

Genzyme lance un site web sur la maladie de Gaucher | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it

Le laboratoire Genzyme, filiale du groupe Sanofi, lance un site web dédié à la maladie de Gaucher : gaucherfrance.fr.


Via Philippe Marchal/Pharma Hub
more...
No comment yet.
Rescooped by Lionel Reichardt / le Pharmageek from TabletsOnWeb
Scoop.it!

Top 20 des laboratoires #Pharma en 2013 d'après IMS Health

Top 20 des laboratoires #Pharma en 2013 d'après IMS Health | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it

Top 20 des laboratoires #Pharma en 2013 d'après IMS Health pic.twitter.com/D7ZDC76FFX


Via TabletsOnWeb
more...
No comment yet.
Rescooped by Lionel Reichardt / le Pharmageek from Social Media and Healthcare
Scoop.it!

Are You on the Right Side of the Digital Tipping Point?

Are You on the Right Side of the Digital Tipping Point? | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it

The world is going native — and doctors who want to remain relevant should too.

No, we’re not talking about adopting local customs when traveling (or forgoing underwear). We’re talking about digital natives, i.e., people who were born during or after the general introduction of digital technologies and, therefore, have been interacting with such technologies all their lives.

(If that’s not you — if you’re, say, 45 or older and can remember more analog-driven times — then you’re what demographers would call a digital immigrant.)

And those millions of digital natives are not just posting cat videos or playing videogames. Among them are the increasing number of doctors who began their careers after the Internet went mainstream and, like their contemporaries, have relied on interactions through connective digital technologies for their entire professional career.

And, if the folks at LBi Health are right, this year represents a tipping point: For the first time (and from here on out), more doctors (51%) will be digital natives than digital immigrants. It may not sound like a major upheaval but, ready or not, the ramifications promise to disrupt every aspect of the profession.

Digital doctors: Not surprisingly, younger doctors are among the most avid adopters of digital technology. According to Kantar Media, 87% of doctors ages 35 and younger use a smartphone for professional purposes vs. 84% for those ages 35–44, 74% for those ages 45­–59 and 59% of those ages 60 and older. And social media usage among doctors ages 26–55 is 22 percentage points higher than for those ages 56–75 (87% vs. 65%), says MedCity News.

Digital patients: Young doctors aren’t the only ones glued to their smartphones and social media feeds. Younger patients instinctively turn to the Internet when considering medical procedures, conducting online searches, consulting medical websites and reading reviews from others to a much greater degree than their older counterparts. When the time comes to contact potential providers, who do you think they’re likely to turn to — those they’ve gained some familiarity with or those they’ve never heard of?

Digital marketing: The above ability to “get to know” — or at least get a sense of — a doctor before meeting him or her is arguably as fundamental a shift as the digital one that enables it. As such, it requires an equally fundamental shift in how doctors interact with people who are not just potential patients but also healthcare consumers. If you don’t meet them early in their “decision journey,” there’s a good chance you won’t meet them at all.

It’s a process that’s reinventing marketing in every industry and well captured in this recent post by Jessica Meher of HubSpot. She’s talking about how the changes impact Chief Marketing Officers, or CMOs, but if you change just a couple of words, her post takes on a whole new resonance:

In a time where buyers are already 60% through the buying cycle before they engage with a vendor, [doctors] need to attract [aesthetic consumers] early in the sales cycle, nurture them until ready to purchase, and help turn them into loyal customers. Investing more in mobile or social isn’t what makes a digital [doctor] truly digital. Modern [doctors] inherently understand how buying behavior has changed and how to get through the clutter by creating valuable content and building an inbound marketing foundation.

The foundation will also provide the stability required to stay on the right side of the digital tipping point.


Via Plus91
more...
No comment yet.
Rescooped by Lionel Reichardt / le Pharmageek from New pharma
Scoop.it!

Value in Pharmaceutical Pricing | OECD iLibrary

Value in Pharmaceutical Pricing | OECD iLibrary | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it

Abstract

This study analyses how 14 OECD Countries refer to “value” when making decisions on reimbursement and prices of new medicines. It details the type of outcomes considered, the perspective and methods adopted for economic evaluation when used; and the consideration of budget impact. It describes which dimensions are taken into account in the assessment of “innovativeness” and the consequences of this assessment on prices; it confirms that treatments for severe and/or rare diseases are often more valued than others and shows how countries use product-specific agreements in an attempt to better align value and price.

..

Conclusions

 

The main objective of this report was to explore value-based pricing for pharmaceuticals. In principle, value-based pricing (VBP) can offer better value-for-money for purchasers of pharmaceuticals. It also gives clear signals to pharmaceutical companies that they will be rewarded if their products address the priorities of the purchasers, so in the longer run may reorient pharmaceutical innovation in a more cost- effective direction. However, it is easier to talk of rewarding ‘value’ than it is actually to do so. Is it value to the purchaser that should be the basis of decisions (i.e. some combination of the increase in health and the reduction in other health spending) or the value to society (which would also take into account increased labour force productivity of those who are less sick and those who no longer care for others, amongst other things)? Is there ‘value’ in innovation itself? Countries which use value-based pricing for pharmaceuticals do not make the same choices as to how to determine value. Furthermore, countries which do not have value-based pricing per se may take into account some of the elements used in economic assessments of value in making their decisions. This report attempts to shed light on what impact these different choices make to reimbursement decisions and prices.

...

Read on in the downloadable PDF!

 

Please cite this paper as:

 

Paris, V. and A. Belloni (2013), “Value in Pharmaceutical Pricing”,

 

OECD Health Working Papers, No. 63, OECD Publishing.

 

http://dx.doi.org/10.1787/5k43jc9v6knx-en

 


Via rob halkes
more...
rob halkes's curator insight, April 16, 5:36 AM

Very insightful research!

Just for your appetite, I quote two relevant conclusions:

  • The first, and by no means trivial, conclusion is that the type of health outcomes considered by assessment bodies and decision-makers to inform or make decisions on reimbursement seem to have more in common with each other than differences. (p.58)

  • One substantial difference between the case-study countries is whether they take into account utility for patients as a measure of outcome. Typically, countries using economic evaluation consider utility (Australia, Canada, Sweden, Norway and the United Kingdom) while other countries (e.g. France or Italy) do not. This is expected to have an impact on reimbursement decisions, price levels and relative prices of different categories of products. From the sample of countries and products scrutinized, it was not possible to identify such an impact.(p.58)

Rescooped by Lionel Reichardt / le Pharmageek from All about Pharma by Pharmacomptoir
Scoop.it!

services e-santé et connectivité : les piliers de la transformation digitale des labos pharmaceutiques | Orange Business Services

services e-santé et connectivité : les piliers de la transformation digitale des labos pharmaceutiques | Orange Business Services | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it
Pour les laboratoires pharmaceutiques, on le sait, l’avenir du business n’est pas forcément au beau fixe. Pour ce faire, l’une de leurs perspectives réside certainement dans la transformation digitale et l’évolution vers les services d’e-santé.

Via Pharmacomptoir / Corinne Thuderoz
more...
No comment yet.
Rescooped by Lionel Reichardt / le Pharmageek from Pharma Multichannel Marketing
Scoop.it!

Multichannel Marketing: What Is It and Why It Matters | SAS

Multichannel Marketing: What Is It and Why It Matters | SAS | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it

Multichannel marketing refers to the practice of interacting with customers using a combination of indirect and direct communication channels.


Via Stephen Dunn
more...
No comment yet.
Rescooped by Lionel Reichardt / le Pharmageek from Pharma Marketing
Scoop.it!

How the ePatient Will Revolutionize Pharma Mark...

How the ePatient Will Revolutionize Pharma Mark... | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it

“Pharma companies need marketing strategies that will successfully engage the e-patient in order to continue branding and growing their products.” (How the ePatient Will Revolutionize Pharma Marketing http://t.co/AG8reVXSg4)...


Via Ash Rishi
more...
No comment yet.
Rescooped by Lionel Reichardt / le Pharmageek from parcours de soins
Scoop.it!

Nouveau recul des dépenses de médicaments - Les Échos

Nouveau recul des dépenses de médicaments - Les Échos | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it
Les Échos
Nouveau recul des dépenses de médicaments
Les Échos
Depuis 18 mois, les patients qui refusent que leur pharmacien leur délivre un générique doivent faire l'avance des frais. L'effet dissuasif a joué à plein.

Via Marie Françoise de Roulhac
more...
No comment yet.
Rescooped by Lionel Reichardt / le Pharmageek from Pharma Hub
Scoop.it!

Bayer Launches New Educational Online Resource for Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Bayer Launches New Educational Online Resource for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it

Bayer HealthCare today announced it has launched an educational website for U.S. physicians about a rare life-threatening condition called Chronic Thromboembolic Pulmonary Hypertension (CTEPH). The site – www.CTEPH.com – is designed to increase CTEPH disease awareness among healthcare professionals (HCPs) and educate them on proper CTEPH diagnosis and surgical treatment.


Via Philippe Marchal/Pharma Hub
more...
No comment yet.
Rescooped by Lionel Reichardt / le Pharmageek from [Life sciences & pharma to patient communication | Patient-centric life sciences & pharma companies | Life sciences & pharma multi channel marketing] by VAB Traductions
Scoop.it!

Listen to the Internet: The Patient Communication Opportunity | Eye For Pharma

Listen to the Internet: The Patient Communication Opportunity | Eye For Pharma | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it

Zuzanna Fiminska examines the importance of, and numerous options for, a comprehensive patient communication strategy within the pharmaceutical industry."


Via VAB Traductions
more...
Monica S Mcfeeters's curator insight, April 12, 10:50 AM

This is a long overdue plan. Too many have to be lab rats to find the right medicines, doctors and treatments.. This could help lessen that role if we speak together.

Rescooped by Lionel Reichardt / le Pharmageek from Health Care Social Media Monitor
Scoop.it!

How Pharmaceutical Firms Are Using Social Media to Speak to Patients

How Pharmaceutical Firms Are Using Social Media to Speak to Patients | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it

Historically, the pharmaceutical industry has been a little slow on the uptake when it comes to the adoption of online marketing. But things are changing. In particular, pharma companies are embracing social media as they seek new, effective ways of helping the people using their products gain valuable information and, in turn, build their brand.

Much of the reason for this is that people have become digitally-savvy, as well as digitally-demanding. Research by the Pew Internet & American Life Project, for example, shows that 80% of internet users in the USA – about 93 million Americans – have searched for a health-related topic online.

There is a wealth of healthcare information available on the web. Whether it is reliable or not is open to debate; nevertheless, the research demonstrates just how important the internet is in the sphere of healthcare.

Into this space steps the pharmaceutical firm. Increasingly, drug manufacturers and healthcare providers are moving social media to the centre stage of their business models as they come to recognise its power in engaging patients.

A new report from the IMS Institute for Healthcare Informatics, one of the most wide-ranging analyses of the social media activities of some of the largest pharmaceutical brands, shows that nearly half of pharmaceutical manufacturers are now actively using social to engage with patients on healthcare-related topics.

Key findings:

Twenty-three of the top 50 pharmaceutical companies worldwide are now actively using social media – on Facebook, Twitter or YouTube – to engage with patientsBut only 10 are using all three services for healthcare-related topicsTwitter is used by 22 of the 50 companies studied, YouTube by 17 companies and Facebook by 15 companiesOf the ten pharmaceutical companies that were active across these three channels, Johnson & Johnson was ranked the bestThe overall level of engagement between pharmaceutical companies and patients has steadily increased over the past yearWikipedia is the single leading source of medical information for patients and healthcare professionals

‘Relevant, accurate content’

“Increasingly, patients are turning to social media as an essential forum for obtaining and sharing information related to their health,” explained Murray Aitken, IMS executive director.

“This trend only heightens the need for relevant, accurate content that can be accessed and used throughout the patient journey. Healthcare professionals, regulators and pharmaceutical manufacturers all need to acknowledge the vital role they can and should play as participants in the healthcare conversation.”

Tips for pharma firms starting out on social mediaStart with strategy

A plan of action is crucial to any social media activity. Start by defining your goals. What do you want to do on social? What do you want to accomplish?

Be human – tell stories

Health is a human issue, so offer stories on social media that engage with people. This could be links to case studies, personal blogs or interviews with experts.

Consider translated content

The most successful pharmaceutical companies are global ones. If you are expanding into new markets, consider offering translated social media content to effectively communicate with your new customers.

Pay attention to regulations

Remember that there are restrictions governing the type of marketing activity pharmaceutical companies can offer. Ensure you are up-to-date with regulations.

Start to review and audit

As your social media activity develops, it is crucial that you measure its success. Start analysing your content – see what works and what doesn’t, and make any necessary changes.

 


Via Plus91, John Mark Bwanika, Marie Ennis-O'Connor
more...
No comment yet.
Rescooped by Lionel Reichardt / le Pharmageek from New pharma
Scoop.it!

Boehringer plans to open trial data back to 1998 - PMLiVE

Boehringer plans to open trial data back to 1998 - PMLiVE | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it

Boehringer Ingelheim has announced that it intends to make drug data from clinical trials stemming back to 1998 accessible as part of efforts to improve research transparency within the industry.

The move is part of a collaboration with fellow pharma companies Sanofi, GlaxoSmithKline, Novartis, Roche and ViiV Healthcare on an online platform to handle requests from researchers for trial data.

Boehringer's chairman Dr Andreas Barner made the announcement at Boehringer's annual company meeting yesterday, following up from a commitment to transparency announced at the same meeting in 2013.

Dr Barner, who also heads R&D at Boehringer, explained that the online platform - available at clinicalstudydatarequest.com - currently contained 50 trials available for which to request patient-level data, but the plan is to reach 500 from all involved parties.

“That's quite a job to achieve. but we have to do it in interest of what data and information can be shared with others,” said Dr Barner.

“We have always argued in favour of transparency and now want a more scientific discussion on the level of trial data and have therefore joined up with several research-based pharmaceutical companies in order to make clinical trials data and documents available to a wider public.” ....

read on in the original post here


Via rob halkes
more...
rob halkes's curator insight, April 22, 4:46 AM

Great to see real development in sharing clinical research data!

Rescooped by Lionel Reichardt / le Pharmageek from Publicidad Healthcare
Scoop.it!

La aportación de la industria farmacéutica a la sociedad #hcsmeues

La aportación de la industria farmacéutica a la sociedad #hcsmeues | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it

Via Pere florensa llusa
more...
No comment yet.
Rescooped by Lionel Reichardt / le Pharmageek from Health promotion. Social marketing
Scoop.it!

Pharma’s reputation ‘getting worse’ | Pharmafile

Pharma’s reputation ‘getting worse’ | Pharmafile | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, jobs, events, and service company listings.

Via Giuseppe Fattori
more...
No comment yet.
Rescooped by Lionel Reichardt / le Pharmageek from Pharma Digital
Scoop.it!

Pharma Social Media: Forget ROI, Focus on Patients

Pharma Social Media: Forget ROI, Focus on Patients | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it

While the pressure on pharma companies to maintain profit margins is high the industry needs a better focus on patients as consumers of healthcare.  Part of this focus should be using all the digital tools at their disposal to help consumers navigate the confusing world of empowered healthcare and make choices based on good, clear and easy-to-understand health information.

 

Read more: http://worldofdtcmarketing.com/pharma-social-media-forget-roi-focus-patients/social-media-and-healthcare/


Via Parag Vora
more...
No comment yet.
Rescooped by Lionel Reichardt / le Pharmageek from eHealth revolution
Scoop.it!

Pharma companies : integrating multichannel marketing

Pharma companies : integrating multichannel marketing | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it
External forces are driving #pharma companies to multichannel marketing http://t.co/kcs28qVwFO

Via Ricard Robledo, Xavier SEDES
more...
No comment yet.
Scooped by Lionel Reichardt / le Pharmageek
Scoop.it!

Article > Pharma business model must change radically: KPMG

Article > Pharma business model must change radically: KPMG | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it
"Stop paying lip-service to patients"
more...
No comment yet.
Scooped by Lionel Reichardt / le Pharmageek
Scoop.it!

Santé et médicaments - Centre d'aide Centre de règles AdWords

Quelles sont les règles ?

Les règles Google AdWords imposent des restrictions à la promotion de services et de produits relatifs à la santé. Les conditions diffèrent en fonction
more...
No comment yet.
Rescooped by Lionel Reichardt / le Pharmageek from Pharma
Scoop.it!

"The question of pharma's social ROI has gone the way of the question of the shape of the planet"

"The question of pharma's social ROI has gone the way of the question of the shape of the planet" | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it

Mark Senak writes in his Eye on FDA blog:

 

"The question of ROI [in pharma's use of social media] has gone the way of the question of the shape of the planet.


It may still be worth having the discussion if for no other reason than to actually get grounded in your goals and objectives.  But in fact, we have all moved on and we are not turning back.


It is probably as much good to ask what the ROI is on social media in the same way you might ask what the ROI was on your press releases, your web site, or the electronic socket in wall.


In the end, it may not be a question about the return on investment as much as the cost of not doing business."


Via Andrew Spong
more...
Andrew Spong's curator insight, April 14, 11:15 AM

Nicely put.

José Manuel Taboada's curator insight, April 17, 5:22 AM

So the cuestion may be to be or not to be in Social.

Rescooped by Lionel Reichardt / le Pharmageek from CORPORATE REPUTATION-THE PATIENT PERSPECTIVE
Scoop.it!

The corporate reputation of pharma companies varied significantly in 2013 when assessed by patient groups of different specialties —even between the therapeutic divisions of a single company

The corporate reputation of pharma companies varied significantly in 2013 when assessed by patient groups of different specialties —even between the therapeutic divisions of a single company | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it
Press Release Date: 14-04-2014 Contact: Alexandra Wyke                  email: alexwyke@patient-view.com Tel: 0044-(0)1567-520-965 The corporate reputation of 23 pharma companies in 2013 was analys...

Via PatientView
more...
No comment yet.
Rescooped by Lionel Reichardt / le Pharmageek from Digital, innovation et santé !
Scoop.it!

Genzyme lance un site internet dédié à la maladie de Gaucher

Le site internet gaucherfrance.fr est un service que Genzyme met à disposition des patients atteints de la maladie de Gaucher et de leurs proches pour gérer leur quotidien et être acteur de leur santé.


Via Matthieu BOYER
more...
No comment yet.
Rescooped by Lionel Reichardt / le Pharmageek from e-Marketing for the health-care sector
Scoop.it!

Strategic pharma digital marketing | - World of DTC Marketing.com

Strategic pharma digital marketing | - World of DTC Marketing.com | 9- PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Scoop.it
Strategic pharma digital marketing. strategicpharmamarketing POST SUMMARY: Biopharma organizations should be preparing for the customer of the near future by building capabilities now rather than later and focusing more on the ...

Via Michael Lucht - www.b-innovative.eu
more...
No comment yet.